Breve descripción
El propósito del estudio I CAN es evaluar la seguridad y eficacia de ravulizumab en comparación con placebo para ayudar potencialmente a controlar los síntomas en adultos que tienen IgAN.
Estimated Enrollment
470
Estimated End Date
Jul-30
Trial is for people with
• Be at least 18 years of age • Have a diagnosis of IgAN based on kidney biopsy • Have been treated with stable doses of blood ...
Study Goal
A través del estudio I CAN, pretendemos priorizar la investigación para ayudar a la comunidad global de IgAN.
What is involved for the patient?
Screening: Last approximately six weeks and includes one visit to the site. The study team will review your medical history and ...
About the drug or intervention
The study medication is called ravulizumab (ALXN1210). It is being used in the study for research purposes only. While ravulizumab has ...